Mumbai, June 29 -- The transaction values Pivot Path at Rs 230 crore on a post-money basis. This would enable Strides to realise Rs 100 crore while retaining a 20% stake. The deal also includes a primary capital infusion of Rs 50 crore to accelerate Pivot Path's next phase of growth.

Pivot Path originated within Arco Lab, Strides' Global Capability Centre (GCC), where it developed capabilities across life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services.

As demand from external pharmaceutical and life sciences companies grew, the business evolved into an independent platform serving industry-leading customers. To support its next phase of growth, serve global customers effe...